Tegoprazan: Optimal GI Protection and CV Safety Profile

Retrospective Analysis of Outcomes in Patients on Antiplatelet Therapy After PCI (N=604)
MECHANISMP-CAB (Potassium-Competitive Acid Blocker) — faster and more sustained acid suppression.
SAMPLEPatients after PCI (CAD), taking antiplatelets >6 months.
COMPARISONTegoprazan 50 mg (n=265) vs. Heterogeneous PPI group (n=339).
SAFETYMetabolism via CYP3A4 minimizes drug interactions.
COMPARATIVE CHARACTERISTICS AND TREATMENT OUTCOMES
Parameter Tegoprazan (n=265) PPI (n=339) p-value
Aspirin Use98.1%94.7%0.028
NSAID Use9.8%5.3%0.034
History of Peptic Ulcer4.5%1.8%0.048
Male Sex / Mean Age81.9% / 63.078.8% / 64.00.339 / 0.168
GI Events (ulcers / bleeding)0.4%1.8%0.112
MACE (Cardiac Risks)1.1%2.7%0.183
Death from CV Causes0.4%0%0.258
RISK MATRIX: ADVANTAGE IN TWO DIMENSIONS

*Tegoprazan demonstrates a shift toward the "Low GI risk / Low CV risk" zone, despite an initially more severe patient profile.

0.34 Hazard Ratio (GI Risk)
0.57 Hazard Ratio (CV Risk)
0% Overt GI Bleeding
"Tegoprazan is a safe and effective alternative to PPIs, providing reliable GI protection without increasing cardiovascular risks in patients after PCI."
ABBREVIATIONS: PCI — Percutaneous Coronary Intervention; PPI — Proton Pump Inhibitors; MACE — Major Adverse Cardiovascular Events; GI — Gastrointestinal; CV — Cardiovascular; P-CAB — Potassium-Competitive Acid Blocker.
SOURCE: Lee J, et al. Korean J Helicobacter Up Gastrointest Res 2026.
DOI: 10.7704/kjhugr.2025.0065